<DrugInformationSummary id="CDR0000781156"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Atezolizumab works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells. Atezolizumab is a type of immunotherapy drug called an immune checkpoint inhibitor.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/atezolizumab">Atezolizumab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000702758">atezolizumab</TerminologyLink><GlossaryLink ref="CDR0000781154">atezolizumab</GlossaryLink><USBrandNames><USBrandName>Tecentriq</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>A-teh-zoh-LIZ-yoo-mab</TermPronunciation><MediaLink ref="CDR0000782459" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000782458" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Atezolizumab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Atezolizumab
         is approved to be used alone or with other drugs to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000641933" dictionary="Cancer.gov" audience="Patient">Alveolar soft part sarcoma</GlossaryTermRef></Strong> that has spread to other parts of the body or cannot be removed by surgery.  Atezolizumab is used alone in  adults and children aged 2 years and older.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">Hepatocellular carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000044242" dictionary="Cancer.gov" audience="Patient">liver cancer</GlossaryTermRef>) that has spread to other parts of the body or cannot be removed by surgery. Atezolizumab is used with <GlossaryTermRef href="CDR0000781154" dictionary="Cancer.gov" audience="Patient">bevacizumab</GlossaryTermRef> in patients who have not received <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapy</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045135" dictionary="Cancer.gov" audience="Patient">Melanoma</GlossaryTermRef></Strong> that has a certain <GlossaryTermRef href="CDR0000046063" dictionary="Cancer.gov" audience="Patient">mutation</GlossaryTermRef> in the <GeneName><GlossaryTermRef href="CDR0000561325" dictionary="Cancer.gov" audience="Patient">BRAF</GlossaryTermRef></GeneName> gene. Atezolizumab is used with <GlossaryTermRef href="CDR0000776875" dictionary="Cancer.gov" audience="Patient">cobimetinib fumarate</GlossaryTermRef> and <GlossaryTermRef href="CDR0000702051" dictionary="Cancer.gov" audience="Patient">vemurafenib</GlossaryTermRef> in adults whose cancer has spread to other parts of the body or cannot be removed by surgery.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045323" dictionary="Cancer.gov" audience="Patient">Non-small cell lung cancer</GlossaryTermRef>.</Strong> Atezolizumab is used:<ItemizedList Style="bullet" id="_7"><ListItem>alone after surgery and <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef> chemotherapy in adults with <GlossaryTermRef href="CDR0000045357" dictionary="Cancer.gov" audience="Patient">stage IIA</GlossaryTermRef>, <GlossaryTermRef href="CDR0000682419" dictionary="Cancer.gov" audience="Patient">stage IIB</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045367" dictionary="Cancer.gov" audience="Patient">stage IIIA cancer</GlossaryTermRef> that has the  <GlossaryTermRef href="CDR0000797389" dictionary="Cancer.gov" audience="Patient">PD-L1</GlossaryTermRef> <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef></ListItem><ListItem>alone as the first treatment in adults whose cancer has spread to other parts of the body, has the PD-L1 protein, and does not have a mutation in the  <GeneName><GlossaryTermRef href="CDR0000044397" dictionary="Cancer.gov" audience="Patient">EGFR</GlossaryTermRef></GeneName> gene or the <GeneName><GlossaryTermRef href="CDR0000721252" dictionary="Cancer.gov" audience="Patient">ALK</GlossaryTermRef></GeneName> gene</ListItem><ListItem>with bevacizumab, <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045182" dictionary="Cancer.gov" audience="Patient">carboplatin</GlossaryTermRef> or <GlossaryTermRef href="CDR0000507600" dictionary="Cancer.gov" audience="Patient">paclitaxel albumin-stabilized nanoparticle formulation</GlossaryTermRef> and carboplatin as the first treatment in adults with non-<GlossaryTermRef href="CDR0000046056" dictionary="Cancer.gov" audience="Patient">squamous</GlossaryTermRef> cancer that does not have a mutation in the <GeneName>EGFR</GeneName> gene or <GeneName>ALK</GeneName> gene that has spread to other parts of the body</ListItem><ListItem>with paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as the first treatment in patients with non-squamous cancer that does not have an abnormal <GeneName>EGFR</GeneName> gene or <GeneName>ALK</GeneName> gene and has spread to other parts of the body</ListItem><ListItem>in adults whose cancer has spread to other parts of the body and got worse during or after treatment with platinum chemotherapy<Para id="_9">Atezolizumab is used for patients with cancer that has a mutation in the  <GeneName><GlossaryTermRef href="CDR0000044397" dictionary="Cancer.gov" audience="Patient">EGFR</GlossaryTermRef></GeneName> gene or  <GeneName><GlossaryTermRef href="CDR0000721252" dictionary="Cancer.gov" audience="Patient">ALK</GlossaryTermRef></GeneName> gene if their cancer has worsened after treatment with <GlossaryTermRef href="CDR0000454786" dictionary="Cancer.gov" audience="Patient">FDA</GlossaryTermRef>-approved therapy for these mutations.</Para></ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045327" dictionary="Cancer.gov" audience="Patient">Small cell lung cancer</GlossaryTermRef>.</Strong> Atezolizumab is used with carboplatin and <GlossaryTermRef href="CDR0000045189" dictionary="Cancer.gov" audience="Patient">etoposide</GlossaryTermRef> as the first treatment in adults with <GlossaryTermRef href="CDR0000045911" dictionary="Cancer.gov" audience="Patient">extensive-stage</GlossaryTermRef> cancer.</ListItem>
   
   </ItemizedList><Para id="_8">Atezolizumab is given by <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. It is available in a different form, combined with <GlossaryTermRef href="CDR0000791166" dictionary="Cancer.gov" audience="Patient">hyaluronidase</GlossaryTermRef>, that is given <GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">subcutaneously</GlossaryTermRef>. For more information, see the Drug Information Summary for <DrugRef href="CDR0000816789" url="/about-cancer/treatment/drugs/atezolizumab-and-hyaluronidase-tqjs">Atezolizumab and Hyaluronidase-tqjs</DrugRef>.</Para><Para id="_5">Atezolizumab
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Atezolizumab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/702758">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.73">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a616035.html">Atezolizumab</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.74"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.75">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/atezolizumab-effective-alveolar-soft-part-sarcoma">Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2022/immunotherapy-myocarditis-cause">Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2022/immunotherapy-cancer-biomarker-hla-gene">Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors">Immune Checkpoint Inhibitors</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C106250">Find Clinical Trials for Atezolizumab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2016-05-20</DateFirstPublished><DateLastModified>2025-01-02</DateLastModified></DrugInformationSummary>
